Quest Diagnostics Lifts Guidance on Organic Growth

Dow Jones
10/21

By Dean Seal

 

Quest Diagnostics raised its profit and revenue outlook for the year after strong organic growth and acquisitions boosted its top and bottom lines in the third quarter.

The provider of diagnostic information services said Tuesday that organic revenue growth in the latest completed quarter hit 6.8%, while acquisitions boosted the top line higher.

Quest is now guiding for $10.96 billion to $11 billion in revenue for 2025, up from a prior outlook for $10.8 billion to $10.92 billion, and adjusted earnings of $9.76 to $9.84 a share, up from $9.63 to $9.83 a share.

Shares advanced 2.4% to $195 in premarket trading.

For the third quarter, the Secaucus, N.J., company posted a profit of $245 million, or $2.16 a share, compared with $226 million, or $1.99 a share, in the same quarter a year earlier.

Stripping out one-time items, adjusted earnings were $2.60 a share, topping analyst forecasts by a dime, according to FactSet.

Revenue jumped 13% to $2.82 billion, ahead of analyst estimates for $2.74 billion.

During the quarter, Quest completed the acquisition of select dialysis testing assets from Fresenius Medical Care and separately began to scale clinical lab testing for Fresenius Medical Care's U.S. dialysis customers.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

October 21, 2025 07:12 ET (11:12 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10